Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
03/2003
03/06/2003US20030045517 Nonpeptide substituted spirobenzoazepines as vasopressin antagonists
03/06/2003US20030045516 Chemokine receptor antagonists and methods of use therefor
03/06/2003US20030045515 Cyanoguanidine I kappa B kinase inhibitors as antiproliferative agents for cancer treatment
03/06/2003US20030045496 Treating tumor cells with a selenium prodrug lyase and a selenium-containing prodrug such as selenocysteine, selenohomocysteine, selenomethionine or selenoethionine.
03/06/2003US20030045494 Synthetic oligonucleotides complementary to nucleic acids encoding epidermal growth factor
03/06/2003US20030045493 Oligonucleotide compositions and their use to induce differentiation of cells
03/06/2003US20030045490 Therapeutic antisense phosphodiesterase inhibitors
03/06/2003US20030045479 Novel N-formyl hydroxylamine compounds, compositions and methods of use
03/06/2003US20030045461 Composition and methods of esterified nitroxides gated with carboxylic acids
03/06/2003US20030045459 67 Human secreted proteins
03/06/2003US20030045449 Pharmaceutical combinations for the treatment of neurodegenerative diseases
03/06/2003US20030044950 Phosphodiesterase 10
03/06/2003US20030044898 Nucleotide sequences coding polypeptide for use in the treatment of asthma, parkinson's, heart defects, hypotension, urogenital and bone disorders
03/06/2003US20030044851 Secreted protein HCEJQ69
03/06/2003US20030044845 Novel therapeutic agents for membrane transporters
03/06/2003US20030044810 Methods, compositions, and kits relating to cardiovascular disease
03/06/2003US20030044790 Method of diagnosing of exposure to toxic agents by measuring distinct pattern in the levels of expression of specific genes
03/06/2003US20030044776 Detection of cell death modulators; obtain sample, induce cell death, monitor mitochondrial permeability, detect and evaluate adjustment
03/06/2003US20030044514 Using supercritical fluids to infuse therapeutic on a medical device
03/06/2003US20030044476 Use for its anti-elastase and anti-inflammatory activity on human gums; chewing gum or gel for treating gingivitis
03/06/2003US20030044463 Sustained release of microcrystalline peptide suspensions
03/06/2003US20030044452 Composition for topical administration
03/06/2003US20030044446 A multilayered film comprising a first, water-soluble adhesive layer to be placed in contact with a mucosal surface and a second, water-erodible non-adhesive backing layer that controls residence time; drug delivery from mouth
03/06/2003US20030044439 Treatment of skin with adenosine or adenosine analog
03/06/2003US20030044438 Adapted for improving skin ageing and/or photoageing signs, which cutaneous signs are directly a result of a chronic micro-inflammatory process induced by repeated UV exposures
03/06/2003US20030044425 Adjuvant complex composed of bacterial outer membrane protein proteosomes complexed to bacterial liposaccharide; immunogenic compositions, vaccines and immunotherapeutics
03/06/2003US20030044424 Novel immune enhancing compositions
03/06/2003US20030044390 Applying stresses to blood sampling
03/06/2003US20030044385 Antitumor, anticancer agents
03/06/2003CA2465676A1 Compositions and techniques for localized therapy of restenosis
03/06/2003CA2459974A1 Emu-based formulations for wound treatment related application information
03/06/2003CA2458924A1 Casein derived peptides and uses thereof in therapy
03/06/2003CA2458855A1 Composition for treating parkinson's disease containing a cb1 receptor antagonist and a product activating dopaminergic neurotransmission in the brain
03/06/2003CA2458852A1 Antithrombotic compositions comprising low molecular weight heparin and low molecular weight dermatan sulphate
03/06/2003CA2458849A1 Obesity related genes expressed at least in the hypothalamus, liver or pancreas
03/06/2003CA2458561A1 Yeast membrane protein expression system and its application in drug screening
03/06/2003CA2458476A1 Photoreactive compounds and compositions
03/06/2003CA2458443A1 Bioadhesive compositions and methods for enhanced mucosal drug absorption
03/06/2003CA2458375A1 Substituted-heteroaryl-7-aza¬2.2.1|bicycloheptanes for the treatment of disease
03/06/2003CA2458344A1 Ascorbic acid derivatives, methods of synthesis and pharmaceutical use thereof
03/06/2003CA2458230A1 Method and composition for treatment of ocular hypertension and glaucoma
03/06/2003CA2458226A1 Improved nitroreductase enzymes
03/06/2003CA2458217A1 (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
03/06/2003CA2458131A1 Jnk activation inhibitor
03/06/2003CA2458121A1 Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3-trifluropropanamide derivatives which elevate pyruvate dehydrogenase activity
03/06/2003CA2458011A1 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
03/06/2003CA2457976A1 Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
03/06/2003CA2457974A1 Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof
03/06/2003CA2457879A1 Modulators of bone homeostasis identified in a high-throughput screen
03/06/2003CA2457846A1 Use of heparinoid derivatives for treating and diagnosing diseases that can be treated by heparinoids
03/06/2003CA2457838A1 2,4-disubstituted pyrimidinyl derivatives for use as anticancer agents
03/06/2003CA2457836A1 Preventive and/or remedial agent for disease attributable to arteriosclerotic activity
03/06/2003CA2457532A1 Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof
03/06/2003CA2457488A1 Antimicrobial agent
03/06/2003CA2457341A1 A new extended release oral dosage form
03/06/2003CA2456828A1 Novel genetic products from ashbya gossypii, associated with the structure of the cell wall or the cytoskeleton
03/06/2003CA2456480A1 A combination of quetiapine and zolmitriptan
03/06/2003CA2456350A1 Novel imidazopyridine compounds with therapeutic effect
03/06/2003CA2456349A1 1,2-dihydro-2-oxo-1,8-naphthyridine derivative
03/06/2003CA2456348A1 Platinum complexes and their uses in therapy
03/06/2003CA2455773A1 Substituted-aryl 7-aza¬2.2.1|bicycloheptanes for the treatment of disease
03/06/2003CA2455497A1 Amidine derivatives for treating amyloidosis
03/06/2003CA2455311A1 Rapamycin dialdehydes
03/06/2003CA2449515A1 Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
03/06/2003CA2430267A1 Hydrazinopeptoids and their uses for treating cancers
03/06/2003CA2421499A1 Novel crystals of 1,3,4-oxadiazole derivative, process for producing the same and pharmaceutical agent containing the same as active ingredient
03/05/2003WO2002020566A2 NOVEL MMP-2 DERIVATIVES FOR USE AS INHIBITORS OF INTEGRIN αVβ¿3?
03/05/2003EP1288311A2 Method for testing small pharmaceutically active molecules in the activation of Pax4 and production of insulin producing beta-cells
03/05/2003EP1288299A2 TRNA synthetase
03/05/2003EP1288298A2 TRNA synthetase from Staphylococcus aureus
03/05/2003EP1288297A1 Regulation of mt1-mmp activity
03/05/2003EP1288264A1 Gelling composition
03/05/2003EP1288228A1 BMP-2-derived peptides having osteogenetic activity and osteogenetic accelerator containing the same
03/05/2003EP1288227A1 Coactivator of nuclear receptors
03/05/2003EP1288224A1 Therapeutic peptide derivatives
03/05/2003EP1288223A1 Therapeutic peptide derivatives
03/05/2003EP1288222A1 Peptidic compounds selectively binding to P-selectin
03/05/2003EP1288214A1 Paroxetine methanesulfonate
03/05/2003EP1288206A1 Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors
03/05/2003EP1288205A1 Novel phenylalanine derivatives
03/05/2003EP1288202A1 N-acyltetrahydroisoquinoline derivatives
03/05/2003EP1288199A1 Mmp-12 inhibitors
03/05/2003EP1287827A1 Immunopotentiator
03/05/2003EP1287825A1 Blends comprising a substituted fatty acid or a derivative thereof
03/05/2003EP1287362A2 Compositions and methods for modulating tumor specific expression
03/05/2003EP1287355A2 Methods and compounds for influencing $g(b)3 integrin-dependent intracellular processes
03/05/2003EP1287162A2 Gene expression profiling of inflammatory bowel disease
03/05/2003EP1287159A1 Enzymatic treatment of whey proteins for the production of antihypertensive peptides, the resulting products and treatment of hypertension in mammals
03/05/2003EP1287157A1 Protein markers for pharmaceuticals and related toxicity
03/05/2003EP1287132A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
03/05/2003EP1287131A2 Regulator of g protein signalling (rgs8)
03/05/2003EP1287130A2 Mammalian cytokine receptor subunit proteins, related reagents and methods
03/05/2003EP1287035A1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
03/05/2003EP1287032A2 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof
03/05/2003EP1287028A2 Compositions and methods for the therapy and diagnosis of colon cancer
03/05/2003EP1287020A2 Cancer diagnosis and assays for screening anti-cancer agents
03/05/2003EP1287019A1 Therapeutic approaches to diseases by suppression of the nurr subfamily of nuclear transcription factors
03/05/2003EP1287005A2 Benzoic acid esters having antiplasmid effect
03/05/2003EP1287002A1 Crf receptor antagonists
03/05/2003EP1286995A1 2,7-naphthyridine derivatives
1 ... 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 ... 1564